Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study

Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1]  This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study

Fighting P. aeruginosa (Part II)

At a still earlier stage of development, we found some exciting anti-pseudomonal compounds. First, there is BAL-30072, a sulfactam-derivative.  It has an interesting dual MoA as it works not only as a traditional B-lactam but also as an Fe-chelator blocking bacteria from accessing this essential nutrient [i].  It has very good anti-pseudomonas Continue reading Fighting P. aeruginosa (Part II)